Decline depth
-37.5%
From rolling 252-day high of $8.00, 77d ago.
Past the 30% Amber threshold.
-37.5%
from rolling 252-day high of $8.00 set 2026-05-06 · 77d ago
Current
$5.00
Decline depth
-37.5%
Decline σ
7.1σ
TFC
1/5 bearish
Rolling 252-day high
Up day
Down day
Last 90 trading days · data from Alpaca
Since it joined the list
$RLMD landed on the list 2026-06-04, down 21.1% from its 52-week high that day — now down -37.5%.
That's 14.1 percentage points deeper than the day it joined.
Decline from the 52-week high as it stood on 2026-06-04 (fixed anchor) → today. Split-adjusted, Alpaca. Observed history, not a forecast.
Structural break signals
RLMD qualifies for the Red List on decline depth.
Time-frame continuity
1/5 bearish
Latest bar across daily/weekly/monthly/quarterly/yearly time frames. A bar counts as bearish when it's a 2-Down or a red 3.
Decline sigma
7.1σ
Drop from local high over the last 20 bars, expressed in units of the stock's typical daily volatility (4.25% per day).
Past the ≥6σ Amber threshold.
The structural read
What price action says about RLMD.
RLMD qualifies for the Red List on decline depth — down -37.5% from its rolling 252-day high. Past 30% with the high set inside the last four months — the recency clause that often precedes further breakdown. Depth plus recency: this is the pattern many investors call a falling knife.
Cross-confirmation: decline sigma also reads 7.1σ over 20 bars.
Earnings on file: 2026-05-12. Tiering is unaffected by earnings dates — listings reflect price structure only.
52-week range
52W low $0.55
59.7% of range
52W high $8.00
Sector context · Healthcare
157 other Healthcare tickers are on Broken Stocks.
71
Red List
39
Amber
47
Watch
-34.9%
Median decline
Worst in sector: KRRO (-79.1%). Least-bad: TBPH (-20.1%). See all Healthcare listings →
Related — same sector
Closest decliners to RLMD
Amber List
SRPT
Sarepta Therapeutics, Inc.
Amber List
SGRY
Surgery Partners, Inc.
Amber List
FLGT
Fulgent Genetics, Inc.
Amber List
GYRE
Gyre Therapeutics, Inc.
Amber List
AMPH
Amphastar Pharmaceuticals, Inc.
Amber List
SDGR
Schrodinger, Inc.
Questions about RLMD
What people ask.
Why is RLMD on Broken Stocks?
RLMD qualifies for the Red List on decline depth. It is down -37.5% from its rolling 252-day high of $8.00, set on 2026-05-06 — 77d ago.
Is RLMD a falling knife?
By the most common technical definition — a steep, recent breakdown from a fresh high — yes. RLMD is down -37.5% from its 52-week high of $8.00, set 77d ago. That combination of depth (past the 30% Amber threshold) and recency (high set inside the last 120 days) is the textbook falling-knife pattern. Whether to try to catch it is a separate question — historically most attempts to bottom-pick continue lower before reversing. Broken Stocks flags the pattern; it does not recommend buying or selling.
Is RLMD a buy?
Broken Stocks does not issue buy or sell recommendations. The list is a rules-based technical warning system. It tracks structural decline depth and recency — not company quality, management, fundamentals, or news. Always do your own research and consult a licensed advisor.
Where is RLMD trading inside its 52-week range?
At $5.00, RLMD sits 59.7% of the way from its 52-week low ($0.55) to its 52-week high ($8.00). A reading below 25% indicates price is hugging the bottom of the range; above 75%, the top.
How fast has RLMD been declining?
The current 37.5% decline accrued over 77d, which annualizes to roughly -177.8% per year. Annualized pace is a sanity check — a 30% decline in three months is a different signal than a 30% decline over two years.
How does RLMD compare to its sector?
There are 157 other Healthcare tickers on Broken Stocks: 71 Red, 39 Amber, 47 Watch, with 22 showing recovering structural signals. Median sector decline is -34.9% — RLMD's decline is deeper than the sector median.
Does RLMD's earnings date affect its tier?
No. Tiering is decided purely by decline depth and recency of the rolling-high date. The earnings date on file (2026-05-12) is shown for reference only — listings can move tier between scans based on closing prices, regardless of fundamentals or news events.